Detection of Lung Cancer With Volatile Markers in the Breath*

Michael Phillips, MD; Renee N. Cataneo, MA; Andrew R.C. Cummin, DM; Anthony J. Gagliardi, MD, FCCP; Kevin Gleeson, MD; Joel Greenberg, BS; Roger A. Maxfield, MD, FCCP; and William N. Rom, MD, MPH, FCCP

Study objectives: To evaluate volatile organic compounds (VOCs) in the breath as tumor markers in lung cancer. Alkanes and monomethylated alkanes are oxidative stress products that are excreted in the breath, the catabolism of which may be accelerated by polymorphic cytochrome p450-mixed oxidase enzymes that are induced in patients with lung cancer.

Design: Combined case-control and cross-sectional study.

Setting: Five academic pulmonary medicine services in the United States and the United Kingdom.

Patients and participants: One hundred seventy-eight bronchoscopy patients and 41 healthy volunteers.

Intervention: Breath samples were analyzed by gas chromatography and mass spectroscopy to determine alveolar gradients (i.e., the abundance in breath minus the abundance in room air) of C4-C20 alkanes and monomethylated alkanes.

Measurements: Patients with primary lung cancer (PLC) were compared to healthy volunteers, and a predictive model was constructed using forward stepwise discriminant analysis of the alveolar gradients. This model was cross-validated with a leave-one-out jackknife technique and was tested in two additional groups of patients who had not been used to develop the model (i.e., bronchoscopy patients in whom cancer was not detected, and patients with metastatic lung cancer [MLC]).

Results: Eighty-seven of 178 patients had lung cancer (PLC, 67 patients; MLC, 15 patients; undetermined, 5 patients). A predictive model employing nine VOCs identified PLC with a sensitivity of 89.6% (60 of 67 patients) and a specificity of 82.9% (34 of 41 patients). On cross-validation, the sensitivity was 85.1% (57 of 67 patients) and the specificity was 80.5% (33 of 41 patients). The stratification of patients by tobacco smoking status, histologic type of cancer, and TNM stage of cancer revealed no marked effects. In the two additional tests, the model predicted MLC with a sensitivity of 66.7% (10 of 15 patients), and it classified the cancer-negative bronchoscopy patients with a specificity of 37.4% (34 of 91 patients).

Conclusions: Compared to healthy volunteers, patients with PLC had abnormal breath test findings that were consistent with the accelerated catabolism of alkanes and monomethylated alkanes. A predictive model employing nine of these VOCs exhibited sufficient sensitivity and specificity to be considered as a screen for lung cancer in a high-risk population such as adult smokers.

Key words: breath test; detection; lung cancer; volatile organic compounds

Abbreviations: BMAC = breath-methylated alkane contour; CYP = cytochrome P450; MLC = metastatic lung cancer; NPV = negative predictive value; PLC = primary lung cancer; PPV = positive predictive value; VOC = volatile organic compound

Primary carcinoma of the lung is the leading cause of cancer death in both men and women in the United States. A total of 99,000 men and 78,000 women are affected every year, and 86% of them are dead within 5 years of diagnosis. However, with early detection and treatment, the 5-year survival rate improves dramatically from 20% in patients with stage 3 lung cancer to 70% in patients with stage 1 disease. Researchers therefore have sought screening tests to detect lung cancer in its earliest stages, and several promising new early markers have been proposed, including computer-assisted image analysis of chest radiographs, polymerase chain reaction-
based assays of sputum, fluorescence bronchoscopy, and spiral CT scanning.

In 1971, Pauling et al. reported a new method for the microanalysis of breath that revealed the presence of large numbers of previously undetected volatile organic compounds (VOCs) in normal human breath. It is now known that a sample of breath contains, on average, approximately 200 different VOCs, mostly in picomolar (ie, $10^{-12}$ mol/L) concentrations. We and others have identified apparent new markers of lung cancer among these VOCs, which are predominantly alkanes and methylated alkanes. Until recently, these were empirical observations that could not be readily explained by known pathophysiologic processes. However, a plausible explanation has now emerged from an improved understanding of the mechanisms and kinetics of VOC synthesis and clearance. Alkanes and methylated alkanes in the breath are apparent markers of oxidative stress, which are the toxic effects of reactive oxygen species comprising oxygen free radicals and hydrogen peroxide. Reactive oxygen species are constantly produced in the mitochondria and leak into the cytoplasm where they cause peroxidative damage to proteins, polyunsaturated fatty acids, and DNA. Peroxidative changes to DNA bases may be carcinogenic, and oxidative stress appears to be increased in some cancers, although the evidence for a causal role is lacking. Lipid peroxidation of polyunsaturated fatty acids in cell membranes generates alkanes such as ethane and pentane, which are excreted in the breath, and breath methylalkanes may be products of the same process. Alkanes are metabolized to allyl alcohols by cytochrome P450 (CYP)-mixed oxidase enzymes, and a number of studies have demonstrated that these enzymes are activated in lung cancer. Polycyclic aromatic hydrocarbons in tobacco smoke induce the activity of CYP 1A1 in the lung and placenta, and CYP 1A2 in the liver, resulting in the accelerated metabolism of a number of drugs and the activation of some procarcinogens. These findings provide a rational basis for a breath test for lung cancer. The activation of CYP enzymes in patients with lung cancer may accelerate the degradation of volatile alkanes and monomethylated alkanes that are produced by oxidative stress and result in measurable changes in the composition of the breath.

We have recently reported tests for the set of C4 to C20 alkanes and their monomethylated derivatives in the breath, which appear to vary with the amount of oxidative stress. These breath VOCs were significantly more abundant in older than in younger healthy humans, a finding that is consistent with previous reports that aging is accompanied by increased oxidative stress. We report here an evaluation of this breath test as a marker of disease in patients with lung cancer.

**Materials and Methods**

**Human Subjects**

This investigation involved the following four study groups: (1) patients with primary lung cancer (PLC); (2) patients with metastatic lung cancer (MLC); (3) patients with no histologic evidence of lung cancer; and (4) healthy volunteers. Patients in the first three study groups were classified based on bronchoscopy and biopsy findings following an abnormal chest radiograph finding. The healthy volunteers were recruited in Staten Island, NY, from members of the general population who had no history of cancer, finding. The healthy volunteers were recruited in Staten Island, NY, from members of the general population who had no history of cancer or any other chronic disease. A subgroup of healthy volunteers who were ≥ 55 years of age was selected to serve as a control group for the patients with PLC, all of whom were ≥ 55 years of age (Table 1). A tobacco smoking history was obtained from all subjects, and ex-smokers were defined as having been abstinent from the use of tobacco products for at least 2 years.

Patients were eligible to participate if they were ≥ 18 years of age, could understand the breath collection procedure, could give written informed consent, and did not have a history of previously diagnosed cancer at any site. One hundred seventy-eight patients who had been referred to a pulmonary physician for further evaluation of an abnormal chest radiograph were recruited from the pulmonary services of the following five academic medical centers: Charing Cross Hospital, Imperial College, London, UK (75 subjects); Columbia Presbyterian Medical Center, New York, NY (19 subjects); New York University Medical Center, New York, NY (5 subjects); Penn State Medical Center, Hershey, PA (69 subjects); and St. Vincent’s Medical Center, New York, NY (10 subjects). The 41 healthy volunteers, who were recruited from Staten Island, NY, had no known history of cancer. The research was approved by the institutional review boards of all participating institutions.

**Study Design**

This study included the following two components: a case-control study and a cross-sectional study. The case-control study...
involved patients with PLC and healthy volunteers in the development and initial cross-validation of a statistical prediction model. The cross-sectional study involved two groups of bronchoscopy patients in additional, independent cross-validations (i.e., patients with MLC and patients with negative biopsy findings).

Detection of Lung Cancer

Bronchoscopy was performed according to standard procedures. Intrathoracic lesions were lavaged or brushed for cytology and were biopsied directly using a standard alligator forceps. Parenchymal lesions were evaluated by the lavage of the appropriate airway segment and by transbronchial biopsy under direct fluoroscopic guidance. Lung biopsy specimens were preserved in formalin for microscopic examination by a pathologist. In patients with nondiagnostic findings at bronchoscopy, additional investigations (including serial CT imaging of the chest, needle biopsy, or surgical biopsy) were performed until the diagnosis of cancer was either established or excluded. The clinical stage of the disease was determined according to the International TNM staging system for lung cancer. MLC was defined as cancer from a nonpulmonary primary malignancy metastatic to the lung. Pathologists had no knowledge of the breath test results when the biopsy specimens were examined. The final diagnosis employed for data analysis, of cancer vs no cancer in the bronchoscopy group, was based on the reported histopathology of the biopsy specimens that had been obtained either during bronchoscopy or during subsequent biopsy procedures. Healthy control subjects were assumed to be free of cancer.

Breath Collection and Assay

A portable breath collection apparatus was employed to capture the VOCs in 1.0 L breath on a sorbent trap. The VOCs in 1.0 L room air then were captured on a separate sorbent trap (Fig 2). Subjects wore a nose clip while breathing in and out of the disposable mouthpiece of the apparatus for 2.0 min. Light flap valves in the mouthpiece presented low resistance to respiration, so that breath samples could be collected without discomfort to patients, including those who were elderly and/or had pulmonary disease. Breath samples from bronchoscopy patients were collected prior to the procedure, on the same day. All sorbent traps were sent to the laboratory for an analysis of the VOCs by automated thermal desorption, gas chromatography, and mass spectroscopy. This method has been described in detail elsewhere.6,28 Laboratory personnel (RNC and JG) had no
knowledge of the clinical or pathologic findings when the assay was performed. All subjects were able to contribute a breath sample without any adverse effects.

The physiologic interpretation of breath VOC chromatogram data requires the concept of the alveolar gradient.\textsuperscript{6,29} For a given breath VOC, $V_b$ denotes the area under the curve that is associated with the chromatogram peak for that VOC, and $I_b$ denotes the analogous area associated with the internal standard used to calibrate the instrument (0.25 mL of 2 ppm 1-bromo-4-fluoro-benzene; Supelco; Bellefonte, PA). $V_a$ and $I_a$ denote corresponding areas derived from the associated air sample. The alveolar gradient of the VOC is then determined as:

\[
\text{alveolar gradient} = \frac{V_b/I_b}{V_a/I_a}.
\]

The two terms give the relative abundance of the VOC in breath and air, respectively. For each study subject, the above formula was used to compute the alveolar gradients of each of the C4 to C20 n-alkanes and their monomethylates. The mean alveolar gradients of these VOCs then were computed for the four study groups, and the results were displayed in a series of surface plots.

These plots show the carbon chain length on the $x$-axis, the methylation site on the $z$-axis, and the mean alveolar gradient on the $y$-axis.

**Statistical Analysis**

Forward stepwise discriminant analysis\textsuperscript{30} was used to identify the combination of VOCs that provided the best discrimination between patients with PLC and healthy volunteers. This multivariable technique produces a predictive model (or equation) that estimates the probability of disease for each study subject, predicting lung cancer in subjects having an estimated probability of disease of $>0.5$\textsuperscript{31}.

The accuracy of this model was first tested by cross-validation using a leave-one-out jackknife technique, in which each subject was classified using an equation derived from all other subjects.\textsuperscript{32} This technique was used because the sample size was insufficient to divide the sample into a training set for model development and a validation set for testing that model. The model was further tested in the following two groups of patients that were not used in the derivation of the model: patients with MLC (i.e., those with primary cancer of nonlung sites metastatic to lung); and bronchoscopy patients with negative biopsy findings.

**Results**

Table 1 summarizes the demographics of the study subjects. The breath test identified 80 different C4 to C20 alkanes and monomethylated alkanes that had been either synthesized or catabolized by at least one subject (Fig. 3). Forward stepwise discriminant analysis identified nine of these VOCs as the best set of markers of disease (Table 2 and Fig 4, 5). This combination yielded a sensitivity of 89.6% (60 of 67 patients) and a specificity of 82.9% (34 of 41 patients) when a 0.5 probability of disease was used as the dividing point between a positive and a negative breath test.

Cross-validation using the leave-one-out jackknife procedure (and keeping the 0.5 probability of disease as the threshold) yielded a sensitivity of 85.1% (57 of 67 patients) and a specificity of 80.5% (33 of 41 patients) when a 0.5 probability of disease was used as the dividing point between a positive and a negative breath test.

In patients with MLC, the sensitivity of the model was 66.7% (10 of 15 patients). Bronchoscopy patients with negative biopsy findings were classified as cancer-negative with a specificity of 37.4%.

### Table 1—Demographics of Study Subjects\textsuperscript{*}

<table>
<thead>
<tr>
<th>Variables</th>
<th>No.</th>
<th>Age, yr (Mean, SD)</th>
<th>Male No. (%)</th>
<th>Female No. (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bronchoscopy negative for cancer</td>
<td>91</td>
<td>58.4 (14.2)</td>
<td>41 (45.1)</td>
<td>50 (54.9)</td>
</tr>
<tr>
<td>Primary lung cancer</td>
<td>67†</td>
<td>68.2 (9.9)</td>
<td>48 (71.6)</td>
<td>19 (28.4)</td>
</tr>
<tr>
<td>Metastatic lung cancer</td>
<td>15</td>
<td>66.6 (9.2)</td>
<td>4 (26.7)</td>
<td>11 (73.3)</td>
</tr>
<tr>
<td>Lung cancer, undetermined</td>
<td>5</td>
<td>63.9 (26.3)</td>
<td>3 (60.0)</td>
<td>2 (40.0)</td>
</tr>
<tr>
<td>Healthy volunteers</td>
<td>41</td>
<td>69.6 (12.6)</td>
<td>16 (39.0)</td>
<td>25 (61.0)</td>
</tr>
</tbody>
</table>

\textsuperscript{*}Lung cancer was classified as undetermined when it was not possible to determine with certainty whether it was metastatic to the lung or it had arisen as a lung primary (e.g., adenocarcinoma of indeterminate primary origin).

\textsuperscript{†}Ten small cell and 57 non-small cell cancers.
(34 of 91 patients). The results of cross-validation in healthy volunteers and patients with PLC were stratified by smoking status, histology, and TNM staging (Table 3). In smokers and ex-smokers, the sensitivity was 85.9% (55 of 64 patients) and the specificity was 82.6% (19 of 23 patients), indicating that tobacco smoking does not adversely affect the accuracy of the breath test. Stratification by histologic type and TNM staging of the cancer revealed no marked effects, suggesting that the model’s performance is consistent across these strata. The sample size is insufficient, however, to reach definitive conclusions for individual subgroups.

**Figure 3.** Surface plots of breath test results. The mean alveolar gradient is shown on the vertical axis for C4 to C20 alkanes and their monomethylated derivatives. The horizontal axes identify the specific VOC (eg, the combination of a carbon chain length of 4 and a methylation site of S2 corresponding to 2-methylbutane). Several of the mean alveolar gradients appeared to be reduced in patients with lung cancer compared to age-matched healthy volunteers and to patients with negative bronchoscopy findings. The hypothetical mechanism accounting for these differences is the accelerated clearance of alkanes and methylalkanes by induced CYP polymorphs in patients with lung cancer.

**Table 2—VOCs Used to Identify Patients with Lung Cancer**

<table>
<thead>
<tr>
<th>Order of Entry into Model</th>
<th>Butane*</th>
<th>Tridecane, 3-methyl</th>
<th>Tridecane, 7-methyl</th>
<th>Octane, 4-methyl</th>
<th>Hexane, 3-methyl</th>
<th>Heptane</th>
<th>Hexane, 2-methyl</th>
<th>Pentane</th>
<th>Decane, 5-methyl</th>
</tr>
</thead>
</table>

*Best single discriminator.

**Discussion**

This study demonstrated two main findings. First, a predictive model employing nine breath VOCs was sensitive and specific for lung cancer. Second, the statistical characteristics of the breath test showed only minor changes when subjects were stratified according to a history of tobacco smoking, the histologic type of the cancer, or the TNM stage of the cancer.
The mean alveolar gradients of the alkanes and monomethylated alkanes observed in the breath were predominantly negative in patients with PLC and predominantly positive in the age-matched healthy volunteers (Fig 3, left panels), which is consistent with the findings of previous reports of increased activity of polymorphic CYP in patients with lung cancer. The alveolar gradient of a VOC varies with its rate of synthesis minus its rate of clearance, so that the observed differences in PLC were consistent either with a decreased rate of synthesis (caused by an unknown mechanism) or with an increased rate of clearance (caused by the induction of mixed oxidase enzymes). CYP activation is the basis of an emerging hypothesis for the etiology of lung cancer, which is based on an interaction between inborn risk (a genotype containing several polymorphous CYP enzymes) and environmental toxins (including components of tobacco smoke).

The predictive model for PLC yielded superior specificity when the control group comprised healthy volunteers instead of cancer-negative bronchoscopy patients with abnormal chest radiograph findings. There are at least two possible reasons for this finding. First, not all members of the cancer-free group may have been truly free of cancer. Some may have harbored small foci of cancer that were too small for detection. Bronchoscopy and biopsy are seldom diagnostic in lesions that are $<1.1$ cm in diameter, and false-negative findings are not uncommon, particularly in lesions that are $<2.0$ cm in diameter. Second, some patients with abnormal chest radiograph findings may have harbored a precancerous lesion that induced changes in CYP me-

**Table 3—Effect of Smoking Status, Histology, and TNM Staging on Performance of the Breath Test**

<table>
<thead>
<tr>
<th>Variables</th>
<th>Sensitivity</th>
<th>Specificity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Smokers and ex-smokers</td>
<td>85.9 (55/64)</td>
<td>82.6 (19/23)</td>
</tr>
<tr>
<td>Nonsmokers</td>
<td>66.7 (2/3)</td>
<td>77.8 (14/18)</td>
</tr>
<tr>
<td>Total</td>
<td>85.1 (57/67)</td>
<td>80.5 (33/41)</td>
</tr>
<tr>
<td>Non-small cell cancer</td>
<td>87.8 (50/57)</td>
<td></td>
</tr>
<tr>
<td>Small cell cancer</td>
<td>70.0 (7/10)</td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>85.1 (57/67)</td>
<td></td>
</tr>
<tr>
<td>Stage 1</td>
<td>85.7 (12/14)</td>
<td></td>
</tr>
<tr>
<td>Stage 2</td>
<td>50.0 (1/2)</td>
<td></td>
</tr>
<tr>
<td>Stage 3</td>
<td>90.0 (18/20)</td>
<td></td>
</tr>
<tr>
<td>Stage 4</td>
<td>82.6 (19/23)</td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>84.7 (50/59)</td>
<td></td>
</tr>
</tbody>
</table>

*Values given as % (No. of patients in whom cancer was detected/total No. of patients).

Values given as % (No. of patients in whom cancer was detected/total No. of patients).
used screening tests, such as mammography, for detecting breast cancer. A 1993 mammography study involving 31,000 women reported a PPV of 9% when the test was used to screen women aged 50 to 59 years, and a 1997 mammography study involving 1,007 women aged 14 to 82 years reported a NPV of 98%. These figures suggest that a cancer screening test with comparable statistical properties (ie, PPV, 9%; NPV, 95%) would be considered clinically useful. Table 4 shows the expected outcome of screening 1,000 asymptomatic smokers who were ≥ 60 years of age with the breath test. Of those smokers, 27 will have previously undetected lung cancer, based on the findings of Henschke et al who used chest CT scanning to screen a similar group of subjects. The PPV and NPV of the breath test were 10.8% and 99.5%, respectively, demonstrating that a breath test employed as a primary screen for lung cancer could potentially exhibit greater accuracy than a mammogram employed as a primary screen for breast cancer.

It may be asked, what is the potential role of the breath test in a clinical setting in which highly sensitive and specific techniques for imaging lung cancer, such as spiral CT scanning, are already available? The answer lies in seeing these different technologies as being complementary rather than competitive, each occupying its own niche of safety, cost, and efficacy. High-risk patients could potentially be screened for lung cancer in a rational and cost-effective program, as follows: primary screening with the breath test (low cost); if the results are positive, go to secondary screening with spiral CT scan of the chest (intermediate cost); if that has a positive result, go to final testing with bronchoscopy and biopsy (high cost). In summary, what the breath test potentially may add to existing technology is a safe, noninvasive, sensitive, and specific tool for the primary screening for lung cancer in high-risk populations at a comparatively low cost. We have found in practice that hospital and office staff members can be trained rapidly to collect technically satisfactory breath VOC samples. It would be straightforward to

![Table 4](image-url)

<table>
<thead>
<tr>
<th>Test Result</th>
<th>Lung Cancer</th>
<th>No Cancer</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Positive test result</td>
<td>23 TP</td>
<td>190 FP</td>
<td>213</td>
</tr>
<tr>
<td>Negative test result</td>
<td>4 FN</td>
<td>783 TN</td>
<td>787</td>
</tr>
<tr>
<td>Total</td>
<td>27</td>
<td>973</td>
<td>1,000</td>
</tr>
</tbody>
</table>

*TP = true positive; FP = false positive; FN = false negative; TN = true negative. Sensitivity = TP/(TP + FN) = 85.1% (23/27); specificity = TN/(TN + FP) = 98% (783/787); PPV = TP/(TP + FP) = 10.8% (23/213); NPV = TN/(TN + FN) = 99.5% (783/787).
implement a breath test screening program for at-risk populations because each site would require only a portable breath collection apparatus. Samples are sent to a laboratory for assay with standard instruments that are widely available.

Breath testing has a number of advantages over other proposed methods for the early detection of lung cancer. It is noninvasive, intrinsically safe, comparatively inexpensive, and highly acceptable to patients. Another advantage derives from the hypothetical mechanism, as follows: changes in the breath test should accompany CYP activation that has progressed sufficiently to convert procarcinogens to carcinogens. Hence, changes in the breath test could be observed while the cancer was still in its earliest and most treatable stages. Potentially, this could translate into a reduction in mortality from lung cancer, but confirmation would require another clinical study to determine prospectively the effects of breath test screening on intervention and survival.

We conclude that a breath test for C4 to C20 alkanes and monomethylated alkanes provided a rational new set of markers that identified lung cancer in a group of patients with histologically proven disease. However, this study was limited by the following three main factors: the limited range of presenting disorders among the patients; the comparatively small number of patients with lung cancer; and the comparatively large number of variables in the breath-methylated alkane contour. The latter two factors necessitated cross-validation with a leave-one-out jackknife technique. A preferable cross-validation procedure is to randomly allocate patients to the following two groups: a training set, to derive the statistical model; and a test set, to validate the model. However, this test of cross-validation requires a larger number of patients than were available for this study. Further studies are required to validate the breath test more stringently in a greater number of patients with lung cancer who present with a more diverse range of disorders. Connelly and Inui have identified the criteria for a screening test, which depend both on the disease and the method of screening. The disease must be sufficiently burdensome to the population that a screening program is warranted, the disease must have a long preclinical latent period, and efficacious treatment must be available. The screening method must have acceptable technical performance parameters and must detect the disease at an earlier stage than would be possible without screening, while minimizing false-positive and false-negative results. In addition, early detection must improve disease outcome, and the cost, feasibility, and acceptability of screening and early treatment should be established. The breath test is comparatively low in cost, technically feasible, and acceptable to patients. Based on this study, it appears likely that it could provide earlier detection of lung cancer with an acceptably low rate of false-positive and false-negative results. However, it is not yet known whether it can improve disease outcome. Further studies are needed to confirm these findings and to evaluate the potential value of breath testing in screening for early lung cancer.

ACKNOWLEDGMENTS: We thank Dr. Eugen Sersen for statistical consultation and Dr. Anton Sinniah for assisting with the collection of breath samples.

REFERENCES

16 Risby TH, Schnett SS. Clinical application of breath biomar-
19 Watanabe M. Polymorphic CYP genes and disease predisposition—what have the studies shown so far? Toxicol Lett 1998; 102–103:167–171